TITLE:
Phase I/II Study of Monoclonal Factor IX Concentrate for Factor IX Deficiency

CONDITION:
Hemophilia B

INTERVENTION:
monoclonal factor IX replacement therapy

SUMMARY:

      OBJECTIVES:

      Assess the safety and long-term efficacy of monoclonal factor IX concentrate in patients
      with factor IX deficiency.
    

DETAILED DESCRIPTION:

      PROTOCOL OUTLINE:

      Patients receive monoclonal factor IX replacement therapy as inpatients. Patients with a
      satisfactory response receive further therapy as needed for bleeding for up to 36 months at
      home.
    

ELIGIBILITY:
Gender: All
Age: 12 Years to N/A
Criteria:

        PROTOCOL ENTRY CRITERIA:

        Patients with factor IX deficiency.
      
